

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mahesh Jayachandra Examiner: TBA
 Serial No.: 10/520,089 Group Art Unit: TBA
 Filed: January 4, 2005 Docket: 13860.0001USWO
 Title: METHODS, COMPOSITIONS AND KITS FOR TREATING DAMAGE TO EXCITABLE CELLS

TRANSMITTAL LETTER

Mail Stop IDS
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

23552

PATENT TRADEMARK OFFICE

Dear Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate
- ☒ Information Disclosure Statement
- ☒ Form 1449 w/19 Reference(s); copy of PCT International Search Report
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

Merchant & Gould P.C.
 P.O. Box 2903
 Minneapolis, MN 55402-0903
 202.326.0300

By: Ronald A. Daignault
 Name: Ronald A. Daignault
 Reg. No.: 25,968
 RAD/cmt



S/N 10/520,089

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Mahesh JAYACHANDRA	Examiner:	TBA
Serial No.:	10/520,089	Group Art Unit:	TBA
Filed:	January 4, 2005	Docket No.:	13860.1USWO
Title:	METHODS, COMPOSITIONS AND KITS FOR TREATING DAMAGE TO EXCITABLE CELLS		

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. At least some of the references were cited in an PCT International Search Report mailed August 6, 2004.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided. Enclosed for the Examiner's information is a copy of the International Search Report.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official

communication. Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(202) 326-0330

Date: August 4, 2005


Ronald A. Daignault
Ronald A. Daignault
Reg. No. 25,968



FORM 1449* INFO
OIPR
AUG 04 2005
PATENT & TRADEMARK OFFICE


23552
PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449 	INFORMATION DISCLOSURE STATEMENT	
	IN AN APPLICATION	
	(Use several sheets if necessary)	
Docket Number:	Application Number:	
13860.0001USWO	10/520,089	
Applicant: JAYACHANDRA, Mahesh		
Filing Date: January 4, 2005	Group Art Unit: TBA	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/L.R./		J. A. Boening et. al., "The Effect of Blocking Sodium Influx on Anoxic Damage in the Rat Hippocampal Slice," pp. 263-268, June 1989, Great Britain
/L.R./		Raymond T. Bartus et al., "Calpain Inhibitor AK295 Protects Neurons From Focal Brain Ischemia," pp. 2265-2270, July 29, 1994, Alkermes, Inc., Cambridge, and Department of Pharmacology and Experimental Therapeutics, Tufts University, Boston, Massachusetts, U.S.A.
/L.R./		Raymond T. Bartus et al., "Postischemic Administration of AK275, a Calpain Inhibitor, Provides Substantial Protection Against Focal Ischemic Brain Damage," pp. 537-544, January 18, 1994, Alkermes, Inc., Cambridge, and Department of Pharmacology and Experimental Therapeutics, Tufts University, Boston, Massachusetts, U.S.A.
/L.R./		James A. Spath et al., "Protective Action of Methylprednisolone on the Myocardium during Experimental Myocardial Ischemia in the Cat," pp. 44-51, April 1, 1974, Department of Physiology, University of Virginia, School of Medicine, Charlottesville, Virginia 22901.
/L.R./		Peter Libby et al., "Reduction of Experimental Myocardial Infarct Size by Corticosteroid Administration," pp. 599- 607, June 22, 1972 and revised form October 30, 17, 1972, Departments of Medicine and Pathology, University of California et al.
/L.R./		Roberto Bolli, MD, et al., "Role of Cellular Proteinases in Acute Myocardial Infarction, I. Proteolysis in Nonischemic and Ischemic Rat Myocardium and the Effects of Antipain, Leupeptin, Pepstatin and Chymostatin Administered in Vivo," pp. 671-680, accepted May 13, 1983, Experimental Physiology and Pharmacology, Cardiology Branch, National Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, Maryland.
/L.R./		Roberto Bolli, MD, et. al., "Role of Cellular Proteinases in Acute Myocardial Infarction, II. Influence of in Vivo Suppression of Myocardial Proteolysis by Antipain, Leupeptin and Pepstatin on Myocardial Infarct Size in the Rat," pp. 681-688, accepted May 13, 1983, Experimental Physiology and Pharmacology, Cardiology Branch National Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, Maryland.
/L.R./		Farah Rahman, "The Monophasic Response (MR): Draft, Fax to Ron Daignault," pp. 12, 19-20, December 20, 2001, Tetragrammaton, Inc., Little Canada, MN, USA
/L.R./		Ju YK, et. al., "Hypoxia increases persistent sodium current in rate ventricular myocytes," 1 p., John Curtin School of Medical Research, Australian National University, Canberra, Australia
/L.R./		Raymond T. Bartus, "The Calpain Hypothesis of Neurodegeneration: Evidence for a Common Cytotoxic Pathway," pp. 315-327, 1997, Alkermes, Inc., Cambridge, Massachusetts Tufts University Medical Center Boston, Massachusetts
/L.R./		Marie A. Badalamente, et. al., "Recovery After Delayed Nerve Repair: Influence of a Pharmacologic Adjunct in a Primate Model," pp. 391-397, Department of Orthopaedics, School of Medicine State University of New York, Stony Brook, NY, et al., accepted for publication February 25, 1992
/L.R./		Marie A. Badalamente, et. al., "Neuromuscular Recovery After Peripheral Nerve Repair: Effects of an Orally-Administered Peptide in a Primate Model," pp. 429-437, Department of Orthopaedics, SUNY, Stony Brook et. al., accepted for publication June 15, 1995
/L.R./		Figure 4. "Effect of Rapid Treatment on Acute MI," 1 p., August 2001, WebMD Corp.
/L.R./		Alexander JH, et. al., "Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	



23552
PATENT TRADEMARK OFFICE

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE